US FDA Allows Trial to Proceed for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

Print Friendly, PDF & Email

POTENTIAL TREATMENT FOR FRIEDRICH”S ATAXIA: PSP is a serious neurodegenerative disease that profoundly affects the quality and length of life in adults 1 . Patients are typically severely disabled within 3-5 years of disease onset. It affects an estimated 17,500 adults in the US. In addition to the motor deficits noted above, affected individuals […]